Neuland Labs' first commercial peptide manufacturing module goes operational; Stock sees profit booking
NiveshIQ
NSE: NEULANDLAB · Healthcare
Neuland Laboratories Ltd.
₹23,535.00▼ ₹265.00 (-1.11%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on NEULANDLAB. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Neuland Laboratories Ltd.
Neuland Laboratories Limited is a leading Indian manufacturer and seller of active pharmaceutical ingredients (APIs) with a presence in India, Europe, the United States, and internationally. The company provides custom manufacturing solutions, generic drug substances, peptide APIs, and synthesis services to generic companies, regional and domestic pharmaceutical manufacturers, distributors, and other pharmaceutical and biotechnology companies. With a rich history dating back to 1984, Neuland Laboratories has established itself as a reliable partner in the pharmaceutical industry. The company has recently declared a ₹34 dividend and appointed Dr. Futran, and has also started commercial production at two Telangana units, marking a significant milestone in its growth journey. With a revenue o
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹1,559 Cr +130.60% | ₹1,477 Cr -5.30% | ₹2,023 Cr +37.00% |
| EBITDA Margin | 29.63% | 21.87% | 29.89% |
| Net Profit | ₹300.00 Cr +158.60% | ₹261.00 Cr -13.00% | ₹364.00 Cr +39.50% |
| EPS | ₹233.89 | ₹202.74 | ₹283.71 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Neuland starts first commercial peptide manufacturing module
Neuland Laboratories: కొత్త Peptide ఫెసిలిటీ ప్రారంభం.. 30 మిలియన్ డాలర్ల భారీ పెట్టుబడి
🔒
+ 3 more stories about Neuland Laboratories Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹642 Cr, PAT ₹148 Cr, EPS ₹115.10, EBITDA margin 36.1%. Growth context: revenue QoQ -17.3%, PAT QoQ -30.6%. Street verdict: strong beat, revenue surprise +22.7%, PAT surprise +91.8%.
Management commentary highlights product launches, approvals, and therapy-mix improvement as key drivers of near-term gr...
FY26 (last completed FY): revenue ₹2, 023 Cr, PAT ₹364 Cr, EBITDA margin 29.9%, EPS ₹283.71. Year-on-year: revenue YoY +...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for NEULANDLAB
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track NEULANDLAB alongside your other holdings
Unlock full NEULANDLAB research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Neuland Laboratories Ltd.?
NiveshIQ detects active intelligence signals for Neuland Laboratories Ltd. (NEULANDLAB) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Neuland Laboratories Ltd.?
Neuland Laboratories Ltd. operates in the Healthcare sector with a market capitalisation of ₹2,277,305.2L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.